This article was originally published in The Tan Sheet
FDA's Roger Williams, MD, appointed exec VP and CEO-designate of the U.S. Pharmacopeial Convention beginning Jan. 4. Williams succeeds Jerome Halperin, who announced his departure earlier this year. Williams has served as deputy director for pharmaceutical science at FDA's Center for Drug Evaluation & Research since 1995. He also has been acting director, Office of New Drug Chemistry, from 1995-1996; he also served as associate director for science and medical affairs and director of the Office of Generic Drugs. Williams, 58, is a member of WHO's Expert Committee on Specifications for Pharmaceutical Preparations and has maintained an adjunct faculty position at the University of California at San Francisco throughout his tenure with FDA
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC